NextPharma reaches agreement to provide Wyeth with full service manufacturing of Cytostatics product.
London 21 January 2005
NextPharma Technologies LTD announces that it has reached an agreement with Wyeth on the terms under which NextPharma will contract manufacture Methotrexate 5 mg Lyophilised and Parenteral for Wyeth Benelux and Japanese markets. NextPharma's fully owned subsidiary Laboratoires Thissen S.A. will provide Wyeth with full services including sourcing of actives, technology transfer and process implementation. Production launch is expected to take place during the third quarter 2005. The two companies are also discussing primary commercial terms to include additional formulations.
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical drug development, clinical trials packaging and manufacturingoutsourcing sector. It has nine manufacturing facilities in Belgium, France, Germany employing over 1000 people and has a customer base which includes many of the worlds leading pharmaceutical companies.
Professor Trevor Jones joins the Board of NextPharma
London 11 January 2005
Professor Trevor Jones CBE has been appointed to the Board of NextPharma Technologies Holdings Ltd, the European based company specialising in strategic pharmaceutical outsourcing of product development, manufacturing and logistics services.
Professor Jones, who was until recently Director General of the ABPI, is also a member of the Board of Allergan Inc. and Chairman of the Merlin Bioscience stem cell company ReNeuron.
Prior to his appointment at ABPI, Professor Jones was the main Board Director for R & D at Wellcome PLC.
Dr. John Padfield, Chairman of NextPharma commented, “as one of the fastest growing outsourcing organisations in Europe we are delighted that Professor Jones has joined the Board of NextPharma. We believe that his knowledge and expertise will add significant benefits to our expansion plans both in Europe and further afield. Trevor Jones joins a strong Board of industry-based executives, including Rob Cawthorn, formerly Chairman of Rhone Poulenc Rorer.”
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical drug development, clinical trials packaging and manufacturing outsourcing sector. It has nine manufacturing facilities located in Germany, Belgium and France employing over 1,100 people and has a customer base which includes many of the world’s leading pharmaceutical companies. The CEO of NextPharma is Mr Bill Wedlake and NextPharma’s principal shareholder is Credit Suisse First Boston Private Equity.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.